Inactive Instrument

ENTREMED Share Price Nasdaq

Pharmaceuticals

End-of-day quote Nasdaq
- ^USD	-

08-14	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-13	Casi Pharmaceuticals, Inc. Announces Management Changes	CI

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	2.36M 2.08M 1.97M 1.79M 3.35M 226M 3.38M 23.62M 9.1M 116M 8.85M 8.66M 372M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	24.21M 21.37M 20.22M 18.33M 34.37M 2.32B 34.71M 243M 93.47M 1.19B 90.92M 88.94M 3.82B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.46%	Yield 2024 *	-	Yield 2025	-

08-14	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-13	Casi Pharmaceuticals, Inc. Announces Management Changes	CI
06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-14	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-20	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-20	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

08-14	CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results	AQ
07-01	CASI Pharmaceuticals : Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Active and Chronic Active Antibody-mediated Rejection	PU

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	20/07/2025
Kun Qian DFI	Director of Finance/CFO	44	15/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	31/12/2016

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	31/03/2013
Zhen Bo Su BRD	Director/Board Member	50	20/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	20/03/2023

ENTREMED Share Price Nasdaq

Stocks

Pharmaceuticals

Valuation: ENTREMED

Latest news: ENTREMED

Press Releases: ENTREMED

Managers and Directors: ENTREMED

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.01%	+1.24%	+63.06%	+120.55%	1,056B
JOHNSON & JOHNSON	-1.61%	-0.60%	+47.32%	+71.79%	645B
ABBVIE INC.	-1.12%	-0.72%	+17.98%	+76.63%	465B
ROCHE HOLDING AG	+0.23%	-3.50%	+34.86%	+41.30%	335B
NOVARTIS AG	+0.30%	+3.37%	+21.41%	+30.19%	275B
ASTRAZENECA PLC	-0.61%	-0.38%	+10.73%	+13.08%	255B
AMGEN INC.	+1.32%	+3.27%	+54.63%	+57.63%	229B
GILEAD SCIENCES, INC.	-0.61%	-0.91%	+34.33%	+101.87%	188B
NOVO NORDISK A/S	-0.87%	-1.11%	-27.62%	-60.83%	169B
Average	-0.26%	-0.12%	+28.52%	+50.25%	401.8B
Weighted average by Cap.	-0.31%	+0.24%	+38.73%	+71.00%

	2024	2025
Net sales	28.54M 25.18M 23.83M 21.61M 40.51M 2.74B 40.91M 286M 110M 1.4B 107M 105M 4.5B	20.71M 18.28M 17.29M 15.68M 29.4M 1.99B 29.69M 207M 79.96M 1.01B 77.77M 76.08M 3.27B
Net income	-39.26M -34.65M -32.78M -29.73M -55.73M -3.77B -56.28M -393M -152M -1.92B -147M -144M -6.19B	-48.06M -42.41M -40.13M -36.39M -68.23M -4.61B -68.9M -481M -186M -2.35B -180M -177M -7.58B
Net Debt	6.05M 5.34M 5.05M 4.58M 8.59M 581M 8.67M 60.6M 23.36M 296M 22.72M 22.22M 954M	21.85M 19.29M 18.25M 16.55M 31.03M 2.1B 31.33M 219M 84.37M 1.07B 82.06M 80.28M 3.45B